CTA is governed by a Board of Directors who are responsible for the strategic direction of the organisation, the Corporate Governance and the management of the Chief Executive Officer. The Board comprises eight members, five of whom are nominated by the member institutions, and three who are independently appointed by the Board.
Professor Andrew Scott is the current Board Chairperson, and has had significant experience in the management and strategic direction of CTA thorough his previous role as Board member.
Board members bring a mix of skills required to contribute to the strategic direction of an organisation acting as a sevice provider in the field of clinical trial management.
Chairman: Professor Andrew Scott
Research Institutes representative
FAANMS FAICD MD DDU FRACP ECFMG MBBS (Hons)
Andrew currently holds the positions of Scientific Director of PET, Department of Molecular Imaging and Therapy, Austin Health, and Laboratory Head at the Olivia Newton-John Cancer Research Institute. He is one of Australia’s top clinician/scientists with great experience in both preclinical and clinical drug development. In addition, he is on the Board of many significant organisations including the Australian Nuclear Science and Technology Organisation (ANSTO), World Federation of Nuclear Medicine and Biology, of which he is the current President, and Chair of the International Relations Committee, Australian and New Zealand Society of Nuclear Medicine (ANZSNM). He is also a Fellow of the Australian Institute of Company Directors.
Andrew has published over 260 peer reviewed papers and 20 book chapters, principally in the areas of oncology and molecular imaging. Invited reviews in leading journals include Nature Reviews Cancer and Cancer Research. He is actively involved in the training and mentoring of young scientists and clinicians and currently supervises several doctoral students in addition to post-doctoral fellows and Nuclear Medicine trainees.
Dr Peter Briggs
Metropolitan Sites representative
Dr Peter Briggs has broad experience in Medical Oncology and Clinical Haematology, with particular interests in lung cancer, breast cancer and haematoncology.
Dr Briggs is Head of the Medical Oncology department at Southern Health. He has a long clinical career in general clinical oncology in private & public practice. Over recent years he has focused particularly on lung cancer management and clinical research in this field. In addition to his duties at the Monash Cancer Centre, Dr Briggs conducts a private medical oncology practice at Moorabbin Specialist Centre.
Professor John Seymour
Metropolitan Sites representative
MBBS FRACP PhD
Professor Seymour is the Director of Cancer Medicine at Peter Mac and a member of many scientific committees including the Victorian Government Consultative Council on Human Research Ethics, Scientific Advisory Committees for the International Workshop on NHL, International Conference on Malignant Lymphoma, and Board of Directors of the International Extranodal Lymphoma Study Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group and is a frequently invited speaker nationally and internationally. He is the Editor-in-Chief of Leukemia and Lymphoma and on the editorial boards of the Journal of Clinical Oncology, British Journal of Haematology, and Leukemia Research. He has also authored 13 book chapters, more than 300 peer-reviewed publications (which have been cited more than 8,000 times), and 500 conference abstracts. Heavily committed to clinical and translational research, Professor Seymour is national study chairman for 12 ongoing national or international clinical trials.
Dr Mark Shackleton
Metropolitan Sites representative
MBBS PhD FRACP
Prof Mark Shackleton is the Director of Oncology at Alfred Health, a Professor of Oncology at Monash University, a Victorian Cancer Agency Clinical Research Fellow, Chair of the Australian and New Zealand Melanoma Trials Group and Head of the Cancer Development and Treatment Laboratory at the Monash Central Clinical School at Alfred. After training in medical oncology and at the Ludwig Institute in Melbourne, Dr. Shackleton undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and post-doctoral work at the University of Michigan, USA. He was awarded the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, a 2011 Pfizer Australia Fellowship, and in 2012 was awarded the Australian Science Minister’s Prize for Life Scientist of the Year. His laboratory focuses on understanding mechanisms of cancer initiation and propagation.
Dr Craig Underhill
Regional Sites representative
Dr Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He became a Fellow of the Royal Australasian College of Physicians in 1997, In the mid 90’s Dr Underhill worked as the Senior Clinical Research Registrar at Guy’s Hospital, London. Dr Underhill was a founding partner in the practice in 1999.
BAppSc GradCertMarketing GradDipBusiness (Public Relations)
Michelle Gallaher is the Creative Director of The Social Science. Healthcare and biotechnology are her fields of expertise having worked in biotech start-ups, major teaching hospitals, research organisations and pharmaceutical companies throughout her 20+ year career. As former CEO of the BioMelbourne Network, the peak body for biotech and med-tech in Melbourne, Michelle developed a contact network that spans far more than Melbourne’s innovations sector, reaching as far as Beijing, Manchester, San Diego and Boston. Michelle is a recognised super tweeter in the international biotech space, recently listed as a top 20 tweeter at BIO 2013 and holding the number 1 spot on the BIO top tweets list. She has a passion for Twitter, Instagram, LinkedIn and Pinterest and is a regular blogger on a number of local and international biotech and med-tech sites.
See more at: http://thesocialscience.com.au/
BCom CA(SA) ACA
Colin joined the CTA Board in June 2015.
Colin is a current member of the Aust & NZ Inst of Chartered Accountants and owns a consulting practice offering strategic and financial services to the healthcare sector.
Colin is a “Big 4” trained Chartered Accountant, graduated from the University of Cape Town and gaining his CA (SA) membership. He obtained his Australian ACA accreditation in 1983.
Colin has extensive commercial and technical experience across a broad range of national and global companies. The last 25 years have been spent in the Healthcare space with companies such as Ipsen, Kendle (now INC Research ) , Medisence (Abbott Labs), holding Financial Director and Board positions in these and other organisations.
Dr Julian Clark
BSc(Hons) PhD DU FTSE MAICD
Dr Julian Clark is currently Head of Business Development at the Walter and Eliza Hall Institute in Melbourne and for several years has operated his own consulting business, Julian Clark Consulting Pty Ltd. Drawing on more than 25 years of international and cross-cultural business experience in growing and leading technology and healthcare enterprises, large and small, Julian assists organizations with development, commercialization and organizational strategies to secure sustainable growth.
Dr Clark has many years direct experience in developing and commercializing pharmaceuticals, biotechnologies, laboratory instrumentation and industrial processes and consumer products. His broad international experience has been gained through senior positions in Pharmacia, Biochrom and others in Sweden, Great Britain, Japan, North America, India and Australia. In recent years he has been particularly active in translating business opportunities across the public-private interface.
Dr Clark was also the founding CEO of the Cancer Therapeutics CRC and is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a Member of the Australian Institute of Company Directors. He has a PhD from the University of Glasgow and an Honorary Doctorate from the University of South Australia. Currently, Julian is a Director of Alchemia Limited and Cancer Trials Australia, Chair of the Advisory Board, Sansom Institute, University of South Australia; and an Associate of the Centre for R&D Leadership, University of Melbourne.
Dr Julian Clark is a member of the Finance & Audit Subcommittee.
Dr Kurt Lackovic
CEO and Board Secretary
BAppSc (Hons) PhD GAICD
Dr Lackovic commenced as CEO of Cancer Trials Australia in January 2017.
Kurt has a PhD in chemistry and a post-doctorate in medical genetics (University of Umeå, Sweden). He is a Graduate of the Australian Institute of Company Directors, and a member of the Licensing Executives Society of Australia and New Zealand, Ausbiotech and the NHMRC Research Translation Faculty.
Kurt has extensive experience in leading complex academic and clinical programs, strong connections to Industry, and strategic linkages to senior executives in Government and major teaching Hospitals. He has worked in early stage drug discovery with a focus on oncology targets, management of WEHI’s High Throughput Screening Facility, led multiple Cancer Therapeutics CRC projects involving national and international partners, and has overseen day-to-day management of the Melbourne Genomics Health Alliance.